Recce Pharmaceuticals Announces Safety Committee Approves Next Dose of RECCE® 327 at 3,000mg in Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
Independent Safety Committee approves next cohort dosing of RECCE® 327 (R327) at two faster infusion…